Response Genetics, Inc. to Hold Annual Meeting of Shareholders Tuesday, June 17, 2008 at 1:00 pm EDT

Business Wire,  June 16, 2008  

• E-mail
• Print
• Link

LOS ANGELES -- Response Genetics, Inc. (NASDAQ:RGDX) today announced that it will hold its Annual Meeting of stockholders on Tuesday, June 17, 2008, beginning at 1 p.m. EDT.

The items for consideration at the meeting are included in the Proxy Statement, which has been mailed to shareholders of record on May 20, 2008.

Interested parties may access the Annual Meeting via a webcast by visiting the Response Genetics Web site at www.responsegenetics.com. The webcast will be archived on the company's Web site under "Investor Relations."

About Response Genetics, Inc.

Response Genetics, Inc. ("RGI") (the "Company") (NASDAQ: RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company was founded in 1999, and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of RGI related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze cancer samples, the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, the Company's ResponseDx:Lung[TM] and ResponseDX:Colon[TM] tests, and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions.

These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

COPYRIGHT 2008 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning